Thyrotropin-secreting pituitary adenomas are aggressive, invasive tumors that respond poorly to available surgical and medical treatments. Inappropriate release of thyrotropin by these tumors can result in hyperthyroidism. We treated five patients who had thyrotropin-secreting pituitary adenomas with the long-acting somatostatin analogue SMS 201-995, which was administered by subcutaneous injection in doses of 50 to 100 micrograms every 8 to 12 hours. Serum levels of thyrotropin were dramatically reduced by treatment in four of the five patients, and levels of another tumor marker, the alpha-subunit of thyrotropin, were reduced in all five. In two patients with hyperthyroidism due to production of excess thyrotropin by the tumor, treatment with the somatostatin analogue resulted in a sustained euthyroid state. One patient who was treated for more than 16 months had a persistent reduction in serum levels of thyrotropin and iodothyronines. We conclude that SMS 201-995 is an effective means of controlling hypersecretion of thyrotropin and the associated hyperthyroidism due to thyrotropin-secreting pituitary tumors.
This article has been cited by other articles:
Lu, C., Willingham, M. C., Furuya, F., Cheng, S.-y.
(2008). Activation of Phosphatidylinositol 3-Kinase Signaling Promotes Aberrant Pituitary Growth in a Mouse Model of Thyroid-Stimulating Hormone-Secreting Pituitary Tumors. Endocrinology
149: 3339-3345
[Abstract][Full Text]
van der Hoek, J., Lamberts, S. W J, Hofland, L. J
(2007). Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas. Eur J Endocrinol
156: S45-S51
[Abstract][Full Text]
Daousi, C, Foy, P M, MacFarlane, I A
(2007). Ablative thyroid treatment for thyrotoxicosis due to thyrotropin-producing pituitary tumours. J. Neurol. Neurosurg. Psychiatry
78: 93-95
[Abstract][Full Text]
Woodmansee, W. W., Kerr, J. M., Tucker, E. A., Mitchell, J. R., Haakinson, D. J., Gordon, D. F., Ridgway, E. C., Wood, W. M.
(2006). The Proliferative Status of Thyrotropes Is Dependent on Modulation of Specific Cell Cycle Regulators by Thyroid Hormone. Endocrinology
147: 272-282
[Abstract][Full Text]
Caron, P., Arlot, S., Bauters, C., Chanson, P., Kuhn, J.-M., Pugeat, M., Marechaud, R., Teutsch, C., Vidal, E., Sassano, P.
(2001). Efficacy of the Long-Acting Octreotide Formulation (Octreotide-Lar) in Patients with Thyrotropin-Secreting Pituitary Adenomas. J. Clin. Endocrinol. Metab.
86: 2849-2853
[Abstract][Full Text]
Kuhn, J. M., Arlot, S., Lefebvre, H., Caron, P., Cortet-Rudelli, C., Archambaud, F., Chanson, P., Tabarin, A., Goth, M., Blumberg, J., Catus, F., Ispas, S., Beck-Peccoz, P.
(2000). Evaluation of the Treatment of Thyrotropin-Secreting Pituitary Adenomas with a Slow Release Formulation of the Somatostatin Analog Lanreotide. J. Clin. Endocrinol. Metab.
85: 1487-1491
[Abstract][Full Text]
Brucker-Davis, F., Oldfield, E. H., Skarulis, M. C., Doppman, J. L., Weintraub, B. D.
(1999). Thyrotropin-Secreting Pituitary Tumors: Diagnostic Criteria, Thyroid Hormone Sensitivity, and Treatment Outcome in 25 Patients Followed at the National Institutes of Health. J. Clin. Endocrinol. Metab.
84: 476-486
[Abstract][Full Text]
James, R. A., Sarapura, V. D., Bruns, C., Raulf, F., Dowding, J. M., Gordon, D. F., Wood, W. M., Ridgway, E. C.
(1997). Thyroid Hormone-Induced Expression of Specific Somatostatin Receptor Subtypes Correlates with Involution of the TtT-97 Murine Thyrotrope Tumor. Endocrinology
138: 719-724
[Abstract][Full Text]
Previous
